Why is Medicamen Biotec falling/rising?

As of 04-Jul, Medicamen Biotech Ltd is experiencing a decline in its stock price, currently at 402.00, which reflects a decrease of 5.1 or 1.25%. The stock has underperformed its sector today by 1.76%, and it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. Additionally, the delivery volume has decreased significantly, falling by 30.12% against the 5-day average, indicating a drop in investor participation. Over the past week, the stock has declined by 2.97%, and it has shown a substantial year-to-date decline of 21.06%, which is indicative of its consistent underperformance against the benchmark indices.
In the broader market context, while the Sensex has gained 3.01% over the past month, Medicamen Biotech's performance has been notably poor, with a 6.79% decline in the same period. This trend of underperformance is further highlighted by the stock's returns over the last three years, where it has generated a return of -39.11% compared to the Sensex's 56.73% gain. The company's financial health is also concerning, with a low return on capital employed (ROCE) of 5.30% and a significant drop in net sales and cash reserves, which contribute to its weak long-term growth prospects. Overall, these factors suggest that the stock's decline is driven by both poor operational performance and a lack of investor confidence.